Perrigo (PRGO) Gets FDA Approval for Generic Gynazole 1
Tweet
Share
E-mailGet Alerts PRGO Hot Sheet
Join SI Premium – FREE
Perrigo Company (Nasdaq: PRGO) announced that it has received final approval from the U.S. Food and Drug Administration for its abbreviated new drug application (ANDA) for butoconazole nitrate 2% vaginal cream, the generic equivalent of Gynazole·1.
Perrigo was the first applicant to submit a substantially complete ANDA with a paragraph IV certification and is entitled to 180-days of marketing exclusivity. Perrigo is working exclusively with KV Pharmaceutical Company (NYSE: KV-A) on a collaboration to launch the product by the end of calendar year 2012.
Perrigo was the first applicant to submit a substantially complete ANDA with a paragraph IV certification and is entitled to 180-days of marketing exclusivity. Perrigo is working exclusively with KV Pharmaceutical Company (NYSE: KV-A) on a collaboration to launch the product by the end of calendar year 2012.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Space-Eyes names four directors ahead of planned Nasdaq listing
- RenX Enterprises agrees to sell Georgia property for $2.6M
- Robo.ai names Hao Wang of Changer.ae to its board of directors
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
